文献速递浆细胞疾病淋巴瘤造血干细胞移植与细胞治疗

联合T细胞去除与移植后环磷酰胺的非清髓性单倍体造血干细胞移植诱导免疫耐受

Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide.
PubMed 文献 · Blood Adv · 2017-10-30

该研究在小鼠中证明,非清髓性预处理下联合高剂量移植后环磷酰胺与T细胞去除的大剂量单倍体造血干细胞移植可克服移植物排斥;并在2例多发性骨髓瘤和1例霍奇金淋巴瘤患者中评估,其中2例成功植入并维持缓解且无移植物抗宿主病,另1例未获嵌合但后续成功接受全清髓性单倍体移植。

要点

  • 小鼠非清髓性预处理下,高剂量移植后环磷酰胺联合T细胞去除大剂量单倍体移植可克服排斥。
  • 2例多发性骨髓瘤和1例霍奇金淋巴瘤患者接受该方案,2例植入并维持缓解,无移植物抗宿主病。
  • 酶联免疫斑点分析显示对供者细胞免疫耐受,为细胞治疗和器官移植提供平台。

核心结论

  • 研究结果表明,一种新型且更安全的非清髓性单倍体造血干细胞移植为细胞治疗和器官移植前的免疫耐受诱导提供了平台。

研究设计与样本

  • 研究先在小鼠中评估非清髓性预处理下联合高剂量移植后环磷酰胺与T细胞去除的大剂量单倍体造血干细胞移植,随后在2例多发性骨髓瘤和1例霍奇金淋巴瘤患者中评估该方案。

主要发现

  • 首例多发性骨髓瘤患者随访25个月,髓系和B细胞谱系呈完全供者型嵌合,T细胞 compartment 呈混合嵌合。
  • 第二例多发性骨髓瘤患者未获得嵌合,但该方案低毒性使该患者后续成功接受全清髓性单倍体造血干细胞移植。
  • 第三例患者接受略高剂量全身照射预处理后迅速植入。
  • 所有患者均维持缓解且无移植物抗宿主病;两例植入患者能够控制巨细胞病毒再激活。
  • 酶联免疫斑点分析显示对供者细胞的免疫耐受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The establishment of safe approaches to attain durable donor-type chimerism and immune tolerance toward donor antigens represents a major challenge in transplantation biology. Haploidentical hematopoietic stem cell transplantation (HSCT) is currently used for cancer therapy either as a T-cell-depleted megadose HSCT following myeloablative conditioning or with T-cell-replete HSCT following nonmyeloablative conditioning (NMAC) and high-dose posttransplant cyclophosphamide (PTCY). The latter approach suffers from a significant rate of chronic graft-versus-host disease (GVHD), despite prolonged immunosuppression. The use of T-depleted grafts, although free of GVHD risk, is not effective after NMAC because of graft rejection. We now demonstrate in mice conditioned with NMAC that combining the power of high-dose PTCY with T-cell-depleted megadose HSCT can overcome this barrier. This approach was evaluated in 2 patients with multiple myeloma and 1 patient with Hodgkin lymphoma. The first myeloma patient now followed for 25 months, exhibited full donor-type chimerism in the myeloid and B-cell lineages and mixed chimerism in the T-cell compartment. The second myeloma patient failed to attain chimerism. Notably, the low toxicity of this protocol enabled a subsequent successful fully myeloablative haploidentical HSCT in this patient. The third patients was conditioned with slightly higher total body irradiation and engrafted promptly. All patients remain in remission without GVHD. Both engrafted patients were able to control cytomegalovirus reactivation. Enzyme-linked immunospot analysis revealed immune tolerance toward donor cells. Our results demonstrate a novel and safer nonmyeloablative haplo-HSCT offering a platform for immune tolerance induction as a prelude to cell therapy and organ transplantation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Aversa F, Bachar-Lustig E, Or-Geva N, et al. Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide. Blood Adv. 2017. PMID: 29296864. doi:10.1182/bloodadvances.2017009423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。